Overview

Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis

Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is the evaluation of the efficacy and safety of RPH-104 treatment in patients with recurrent pericarditis. Pharmacokinetic and pharmacodynamic parameters of RPH-104 multiple doses in this patient population will be assessed as well.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
R-Pharm Overseas, Inc.
Collaborators:
DM 365, LLC
Keystat, LLC